Following positive results from a Phase 3 clinical study, United Therapeutics plans to submit an application to the U.S.
Articles by Marisa Wexler, MS
GSK (formerly called GlaxoSmithKline) has acquired rights to HS235, an experimental treatment for pulmonary hypertension (PH), now…
Global advocacy group Phaware has launched a new app, called…
People with pulmonary arterial hypertension (PAH) who were treated with the inhaled therapy seralutinib in a clinical trial tended…
In pulmonary arterial hypertension (PAH), blood vessel cells in the lungs release exosomes, or cellular shipping containers, filled with…
Treatment with molecular shipping containers called extracellular vesicles, loaded with a signaling molecule called cAMP, reduced the severity of…
Mutations in the gene SOX17 are linked to a severe form of pulmonary arterial hypertension (PAH) that most often manifests…
Researchers using computational analyses of genetic data have identified three age-related proteins that may play key roles in the progression…
Cereno Scientific announced it will broaden development of its experimental treatment CS014 to include pulmonary hypertension associated with…
Artificial intelligence (AI) tools developed by Etiometry may help to predict, among other outcomes, the length of a patient’s…
A weight-based dose regimen of Uptravi (selexipag) for children with pulmonary arterial hypertension (PAH) achieves drug exposure similar…
Two Phase 3 clinical trials are now recruiting participants to test Tenax Therapeutics‘ experimental therapy TNX-103 (oral levosimendan) in…